LUCD Earnings

LUCD reported its earnings on 2026-03-27, showcasing a revenue of against an estimate of 1.40M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.08 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following LUCD's earnings announcement on 2026-03-27, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, LUCD's stock price tends to shift by an average of -1.92% in the 10 days leading up to earnings and 2.86% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate LUCD's annual revenue to reach 1.39M, while the EPS is projected at -0.10. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between LUCD's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, LUCD's stock price typically moves by -1.92% in the 10 days before its earnings and 2.86% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.10 and revenue of 1.39M.

The earnings call highlights strong financial management with controlled expenses and a positive cash position, despite a recent public offering. The strategic focus on Medicare coverage and commercialization of EsoGuard, paired with promising partnerships and expansion plans, is positive. However, uncertainties in the timeline for Medicare coverage and the need for more commercial payer support slightly temper the outlook. Overall, the sentiment leans positive due to the potential revenue growth and strategic partnerships, but the absence of a clear timeline for Medicare approval keeps it from being strongly positive.